141
Views
2
CrossRef citations to date
0
Altmetric
Original Research

A Prospective Observational Study of Antihemophilic Factor (Recombinant) Prophylaxis Related to Physical Activity Levels in Patients with Hemophilia A in the United States (SPACE)

, , , ORCID Icon, , , , & show all
Pages 883-896 | Published online: 14 Oct 2021

References

  • Aledort L, Mannucci PM, Schramm W, Tarantino M. Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfus. 2019;17(6):479–486. doi:10.2450/2019.0211-19
  • Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Treatment Guidelines Working Group on Behalf of the World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–e47. doi:10.1111/j.1365-2516.2012.02909.x
  • Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1–158. doi:10.1111/hae.14046
  • Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535–544. doi:10.1056/NEJMoa067659
  • García-Dasí M, Aznar JA, Jiménez-Yuste V, et al. Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A. Haemophilia. 2015;21(4):458–464. doi:10.1111/hae.12618
  • Krishnan S, Vietri J, Furlan R, Duncan N. Adherence to prophylaxis is associated with better outcomes in moderate and severe haemophilia: results of a patient survey. Haemophilia. 2015;21(1):64–70. doi:10.1111/hae.12533
  • Manco-Johnson MJ. Collision sports and risk of bleeding in children with hemophilia. JAMA. 2012;308(14):1480–1481. doi:10.1001/jama.2012.13303
  • Negrier C, Seuser A, Forsyth A, et al. The benefits of exercise for patients with haemophilia and recommendations for safe and effective physical activity. Haemophilia. 2013;19(4):487–498. doi:10.1111/hae.12118
  • Broderick CR, Herbert RD, Latimer J, et al. Association between physical activity and risk of bleeding in children with hemophilia. JAMA. 2012;308(14):1452–1459. doi:10.1001/jama.2012.12727
  • Wang M, Álvarez-román MT, Chowdary P, Quon DV, Schafer K. Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports. Blood Coagul Fibrinolysis. 2016;27(7):737–744. doi:10.1097/MBC.0000000000000565
  • Trinchero A, Sholzberg M, Matino D. The evolution of hemophilia care: clinical and laboratory advances, opportunities, and challenges. Hamostaseologie. 2020;40(3):311–321. doi:10.1055/a-1175-6530
  • Carrasco JJ, Pérez-Alenda S, Casaña J, Soria-Olivas E, Bonanad S, Querol F. Physical activity monitoring and acceptance of a commercial activity tracker in adult patients with haemophilia. Int J Environ Res Public Health. 2019;16(20):3851. doi:10.3390/ijerph16203851
  • Qian W, Lam TT, Lam HHW, Li CK, Cheung YT. Telehealth interventions for improving self-management in patients with hemophilia: scoping review of clinical studies. J Med Internet Res. 2019;21(7):e12340. doi:10.2196/12340
  • Anderson A, Forsyth A. Playing it safe: bleeding disorders, sports and exercise; 2005. Available from: http://www.hemophilia.ca/files/PlayingItSafe.pdf. Accessed June 8, 2019.
  • Manco-Johnson MJ, Soucie JM, Gill JC. Joint Outcomes Committee of the Universal Data Collection, US Hemophilia Treatment Center Network. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. Blood. 2017;129(17):2368–2374. doi:10.1182/blood-2016-02-683169
  • Rudrapatna VA, Butte AJ. Opportunities and challenges in using real-world data for health care. J Clin Invest. 2020;130(2):565–574. doi:10.1172/JCI129197
  • Lou M, Ullman M, Baker J, et al. Comparison of clinical characteristics and health care utilization among individuals with hemophilia A and B in the hemophilia utilization group studies (HUGS) cohorts. Presented at: World Federation of Hemophilia 2016 World Congress; July 24-28; 2016; Orlando, FL.
  • Kruse-Jarres R, Oldenburg J, Santagostino E, et al. Bleeding and safety outcomes in persons with haemophilia A without inhibitors: results from a prospective non-interventional study in a real-world setting. Haemophilia. 2019;25(2):213–220. doi:10.1111/hae.13655
  • Khair K, Mazzucconi MG, Parra R, et al. Pattern of bleeding in a large prospective cohort of haemophilia A patients: a three-year follow-up of the AHEAD (Advate in haemophilia A outcome database) study. Haemophilia. 2018;24(1):85–96. doi:10.1111/hae.13361
  • Tsakiris DA, Oldenburg J, Klamroth R, et al. Effectiveness and safety outcomes in patients with hemophilia a receiving antihemophilic factor (recombinant) for at least 5 years in a real-world setting: 6-year interim analysis of the AHEAD international and German studies.Presented at: 62nd American Society of Hematology Annual Meeting; December 5-8, 2020.
  • Young G. New challenges in hemophilia: long-term outcomes and complications. Hematology Am Soc Hematol Educ Program. 2012;2012:362–368. doi:10.1182/asheducation.V2012.1.362.3798344
  • Pipe SW. New therapies for hemophilia. Hematology Am Soc Hematol Educ Program. 2016;2016(1):650–656. doi:10.1182/asheducation-2016.1.650
  • Thornburg CD, Duncan NA. Treatment adherence in hemophilia. Patient Prefer Adherence. 2017;11:1677–1686. doi:10.2147/PPA.S139851